EU/3/20/2265

About

On 22 April 2020, orphan designation EU/3/20/2265 was granted by the European Commission to Janssen-Cilag International N.V., Belgium, for cusatuzumab for the treatment of acute myeloid leukaemia.

Key facts

Active substance
cusatuzumab
Disease / condition
Treatment of acute myeloid leukaemia
Date of first decision
22/04/2020
Outcome
Positive
EU designation number
EU/3/20/2265

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Turnhoutseweg 30
2340 Beerse Antwerp
Belgium
Tel: +353857446696
E-mail: nbuhl@its.jnj.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating